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ABSTRACT  
Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid 
clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore to iden-
tify mutants of the protein sequence that minimize immunogenicity in a target population whilst retain-
ing pharmaceutical activity and protein function. Current approaches are moderately successful in de-
signing sequences with reduced immunogenicity, but do not account for the varying frequencies of dif-
ferent human leucocyte antigen alleles in a specific population and in addition, since many designs are 
non-functional, require costly experimental post-screening. 
Here we report a new method for de-immunization design using multi-objective combinatorial optimiza-
tion that simultaneously optimizes the likelihood of a functional protein sequence at the same time as 
minimizing its immunogenicity tailored to a target population. We bypass the need for three-
dimensional protein structure or molecular simulations to identify functional designs by automatically 
generating sequences using probabilistic models that have been used previously for mutation effect pre-
diction and structure prediction. As proof-of-principle we designed sequences of the C2 domain of Fac-
tor VIII and tested them experimentally, resulting in a good correlation with the predicted immunogenic-
ity of our model. 
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Protein-based drugs (biotherapeutics) are increasingly used to treat a wide variety of diseases1,2. Alt-
hough biotherapeutics show high activity and specificity at the initiation of treatment, the gradual build-
up of a patient immune response is a bottleneck for even wider usage3. This immune response involves 
the formation of anti-drug antibodies (ADAs) that target the biotherapeutic itself and cause loss of effect 
or adverse reactions3-5. A prominent example of this adverse effect is in the treatment of hemophilia A 
(HA) with coagulation Factor VIII, where ADAs develops in 10-15% of all HA patients and as much as 
30% of those patients with the most severe form of HA6. Patients with the highest need for therapy are 
thus least likely to benefit. This correlation between severity of the disease and lack of efficacy follows 
from the fact that the immune system is more likely to recognize the therapeutic Factor VIII as foreign 
the more severe the natural mutation is, where mutations that cause a total loss of Factor VIII production 
are most strongly associated with ADA development7,8.  
 
The reduction of the immunogenicity has thus become a major step in a the development of a biothera-
peutic5. The primary focus of reducing immunogenicity has been on humanized monoclonal antibodies 
(mAbs) that are comprised of foreign complementarity-determining regions in the variable regions, with 
the remainder of human origin, and, more recently, on fully human mAbs using bioengineering tech-
niques9,10. However, these approaches are not generally applicable to other classes of biotherapeutics 
and even humanized and full human mAbs can still induce a clinically relevant anti-drug immune re-
sponse, likely through the CD4+ T-cell mediated adaptive immune system11,12. The CD4+ T-cell activa-
tion is induced by the recognition of linear sequential peptides (called epitopes) derived from the thera-
peutic protein, which are presented on human leucocyte antigen (HLA) class II molecules of antigen 
presenting cells. Therefore, the systematic removal of these epitopes by sequence alteration (termed de-
immunization) has been successfully used as an alternative approach to reduce the immunogenicity of 
mAbs and other therapeutic proteins12-16. 
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In recent years, computational screening approaches have been developed to suggest protein sequences 
with reduced the overall immunogenicity. The simplest approaches focused solely on introducing point 
mutations to reduce the amount of CD4+ T-cell epitopes by applying well-established epitope prediction 
methods17-19. However, the suggested mutations can have a significant impact on the stability and func-
tion of the protein. Naïve approaches not considering the structural impact on the protein will inevitably 
produce inactive designs. More advanced methods therefore try to exclude potentially harmful mutations 
by predicting their impact with various metrics20. The most recent approaches simultaneous optimize the 
number of deleted epitopes as well as the stability of the protein approximated either using structural or 
simple sequence information21,22.  
 
Recent advances in statistical protein modeling now allow to accurately infer the tertiary structure23-27 
and mutational effects28-30 of proteins using evolutionary information contained in an multiple sequence 
alignment of a protein family. The statistical global pairwise entropy model used for protein inference 
accurately captures co-evolving sites within a protein which can be utilized to identify structural and 
functional important position using evolutionary couplings (EC) analysis, infer the protein structure, and 
predicted the effects of mutational changes (referred to as EVmutation).  
 
In this work we present a novel formulation of the de-immunization problem that uses, for the first time 
to our knowledge, the maximum entropy model for protein design solving the inverse inference prob-
lem. Incorporating the maximum entropy model, as opposed to force-field based approaches such as 
FoldX31, has four distinct advantages: (i) The statistical model does not require a known structure or de-
pend on the conditions in which the structure was measured. (ii) It implicitly considers constraints on 
residues from interactions with ligands and other proteins, and (iii) models interactions between muta-
tions rather than early filtering of deleterious singles. (iv) A de-immunization approach using the maxi-
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mum entropy model is likely to generate more viable structures as it minimizes potential damage to pro-
tein function at the same time as minimizing the immunogenicity of the biotherapeutic design. The latter 
can also be achieved by incorporating a force field, such as AMBER32, into the optimization process 
21,22, which however complicates the de-immunization formulation.  
As the frequencies of HLA alleles differ drastically between populations, the immunogenicity of the bio-
therapeutic might differ as well. It is thus imperative to design a biotherapeutic for a specific target pop-
ulation considering their HLA allele frequencies, as opposed to treating each HLA allele equally im-
portant during the design process, as previous methods have done. We therefore developed a new quan-
titative immunogenicity objective that considers the HLA allele distributions within different popula-
tions. The resulting de-immunization model does not require known structural information about the 
protein, summarizes functional and structural information that might not be captured by a structure-
based model, and considers the varying HLA frequencies in different populations. We also demonstrate 
how the resulting bi-objective combinatorial optimization problem can be formulated in a concise man-
ner and solved efficiently for relevant problem sizes with a newly developed distributed solving strategy. 
An experimental validation of the resulting designs confirms that the algorithm can indeed lead to signif-
icantly reduced immunogenicity. 
RESULTS 
Formulation of the de-immunization problem 
The problem of protein de-immunization can be described as identifying amino acid substitutions that 
reduce immunogenicity by removing T-cell epitopes while at the same time keeping the structure and 
function of the protein intact. We therefore define the problem of de-immunization as a bi-objective op-
timization problem. The first objective characterizes the immunogenicity of the target protein with re-
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spect to a set of HLA alleles by applying a start-of-the art, continuous immunogenicity prediction meth-
od (TEPITOPEpan33). The immunogenicity objective 𝐼(𝑆| 𝐻 ,𝑃𝐻 ) combines the immunogenicity of 
each predicted epitope over a certain binding threshold weighted by the HLA allele frequencies 𝑃𝐻   of a 
specific target population represented by their prevalent HLA alleles 𝐻34. The second objective 𝐸(𝑆) 
approximates the protein fitness via the statistical energy of the protein sequence, computed by the pair-
wise maximum entropy model inferred using a multiple sequence alignment (MSA) of the target protein 
family23-27.  
More formally, we define the protein de-immunization problem as follows: Given a protein sequence S 
of length n and a set Mi of possible alterations per position 1 ≤ i ≤ n. We seek a mutant S′ of S with k 
alterations for which S′ i ∈ Mi ∀ 1 ≤ i ≤ n holds and that minimizes: 
argminS'   I S'|H,PH , -E S'  
s. t.              S' ∈ Χ,    
The model therefore optimizes the trade off between these two objectives and produces a set of Pareto-
optimal designs of the protein sequence.  
 
As proof-of-principle, we tested the ability of the model to predict low immunogenic constructs of the 
C2 domain of Factor VIII as the domain is highly immunogenic and involved in the ADA development 
in hemophilia A patients when used therapeutically35,36. 
 
Accurate predictions of mutation effects using EVmutation 
Evolutionary couplings computed from sequence alignments have been used successfully to predict the 
phenotypic effects of mutations28-30,37, as well as the 3D structure shown in earlier work23-27. The ap-
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proach assigns an evolutionary statistical energy to any protein sequence that is hypothesized to corre-
spond to the fitness of the molecule. The computation of the statistical energy of the protein and any 
changes to it after mutation is automatic and does not depend on computing or knowing the 3D struc-
ture. Therefore we reasoned that we could use this statistical model in a generative mode for design 
within the algorithmic de-immunization process. 
As previous work on predicting the effect of mutations suggested that the model accuracy depends on 
the diversity of the sequence alignment and the ability to predict the 3D structure accurately30, we used 
the precision of the total epistatic constraints between residue pairs as an approximation of the model 
validity. Overall, 70 long-range evolutionary coupled residue pairs (ECs) have a probability of at least 
90% of being significant and 65 of these (93% precision) are close in space (less than 5Å; Figure 1A, 
Supplementary material S1) in a 3D structure of Factor VIII’s C2 domain (pdb: 3hny38; Fig. 1B). 
 
To assess how well EVmutation can predict the effects of specific mutations compared to force-field 
methods, we used EVmutation and FoldX predictions in a multinomial and logistic regression to predict 
hemophilia A severity (severe, moderate, and mild) based on patient data collected from the Factor VIII 
variant database (http://www.factorviii-db.org, Supplementary Table S2). Since the severity of HA is 
directly correlated with instability and malfunctioning of Factor VIII, the prediction of disease severity 
can be seen as a proxy for functional and structural effect prediction. The multinomial regression model, 
using the change in statistical energy between mutant and wild type as independent variable, shows a 
moderate ability to predict the clinical outcome (F1-micro of 0.65 ± 0.09, F1-macro of 0.47 ±  0.07).  
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Figure 1: (A) Contact map of Factor VIII’s C2 domain. The gray circles represent the known crystal structure (pdb: 
3hny), while the orange dots represent predicted evolutionary couplings. (B) The tertiary structure of Factor VIII’s 
C2 domain (pdb: 3hny). (C) Statistical energy change density separated by HA severity status (red and yellow) and 
the complete EVmutation landscape of single point mutations (blue). As expected, all known single point mutations 
with known HA severity status reside in the lower percentile of the energy landscape. The severe and moderate HA 
cases are clearly separable from the mild cases using EVmutation prediction. In contrast, the two distributions can 
note be clearly separated using FoldX predictions (D). 
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The performance of a FoldX-based multinomial regression model however was significantly worse 
(one-sided Wilcoxon signed rank test, V=13558, p-value < 2.2e-16; F1-micro of 0.49 ± 0.11, F1-macro 
of 0.35 ± 0.09). We combined the severe and moderate clinical classes and performed a logistic regres-
sion, which improved the prediction performance of the EVmutation-based model (weighted AUC of 
0.72 ±  0.11, weighted F1-score of 0.73 ±  0.11; Supplementary Table S2; Fig. 1C). The FoldX-based 
logistic regression model was again outperformed by the EVmutation model (one-sided Wilcoxon 
signed rank test, V=15633, p-value < 2.2e-16; Fig 1D), but also yielded higher predictive power com-
pared to its multinomial model (weighted AUC: 0.62 ± 0.11, weighted F1 0.58 ± 0.13).  
Strong immunogenic region contains functional sites. 
Initial prediction of epitopes using TEPITOPEpan33 with the three most prevalent HLA alleles in the Eu-
ropean population (accounting for 70% of the patients in Western Europe) resulted in 16 epitopes in 6 
regions of the C2-domain of Factor VIII (UniProt: FA8_HUMAN). The region with the highest scoring 
immunogenicity (residues 2,312-2,340) had nine of the 16 predicted strong binding epitopes (Fig. 2A 
and 2B), making it a prime candidate region for de-immunization mutation design. However there is ev-
idence that this very region might be of high functional importance for the protein; The region is en-
riched for conserved co-variation of residues and contains a known membrane-binding motif38. Eight of 
the top ten evolutionary couplings involve residues in the high immunogenic region (Fig. 2C).  In gen-
eral the region is enriched for strong evolutionary couplings (sign test, s = 124, n = 130, p-value < 2.2e-
16, CI95 = [0.90, 0.98]; Fig. 2A). Hence there is a risk that mutations designed to minimize immunogen-
icity could be detrimental to protein function and the method we have developed here is specifically de-
signed to minimize the risk of both. 
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Figure 2: (A) Immunogenicity screening for three DRB1 alleles with TEPITOPEpan. The blue regions depict the cu-
mulative immunogenicity scores per position and the orange regions depict the EC cumulative summary scores of top 
70 ECs. Six immunogenic regions can be identified based on the in silico screening, where region 2,321 to 2,340 is 
the highest immunogenic region containing 9 out of 16 predicted epitopes and was thus chosen as de-immunization 
target. It is comprised of the highest evolutionary coupling pairs. (B) The tertiary structure of Factor VIII’s C2 do-
main of with highlight immunogenic region selected for de-immunization redesign in blue. (C) The tertiary structure 
of Factor VIII’s C2 domain with marked top eight EC (red spheres) that coincide with the identified immunogenic 
region (blue). 
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De-immunization of Factor VIII’s C2 domain 
We next used our bi-objective de-immunization model to design sequences of the identified highly im-
munogenic region resulting in 21 Pareto-optimal sequences with up to three simultaneous point muta-
tions (Table 1, Fig. 3). Although the model was set up to constrain sequence substitutions solely to the 
identified immunogenic region, the resulting fitness change was optimized based on the interactions 
with all sites in that protein domain.  
 
Table 1: De-immunization results for mutation loads of 𝑘 = 1,2,3. 
ID Mutation Epitopes 𝜟Immunogenicity 𝜟Energy 𝜟FoldX 
wt   16 
  
 
0 V2333E 11 -0.38 1.14 0.95 
1 L2321F 16 2.25 0.83 0.7 
2 Q2335H 16 4.91 0.77 0.07 
3 Y2324L,V2333E 9 -2.16 6.47 0.56 
4 Y2324H,V2333E 10 -1.84 5.96 3.78 
5 R2326K,V2333E 10 -1.84 4.31 2.67 
6 L2321T,V2333E 10 -1.59 3.68 2.13 
7 L2321Y,V2333E 11 -1.01 3.48 1.7 
8 L2321F,V2333E 12 -0.99 1.97 1.66 
9 V2333E,Q2335H 12 0.43 1.93 1 
10 L2321F,Q2335H 17 4.3 1.47 0.57 
11 V2313M,Y2324L,V2333E 8 -2.52 7.99 0.16 
12 L2321T,I2327L,V2333E 8 -2.39 6.47 3.1 
13 L2321F,R2326K,V2333E 10 -2.21 5.32 3.36 
14 V2313M,L2321T,V2333E 9 -1.95 5.16 1.61 
15 L2321F,I2313V,V2333E 10 -1.92 4.92 3.29 
16 L2321F,I2313L,V2333E 10 -1.53 4.61 2.78 
17 V2313T,L2321F,V2333E 10 -1.36 4.58 1.49 
18 V2313M,L2321F,V2333E 11 -1.34 3.52 0.99 
19 L2321F,Y2324F,V2333E 12 -1.05 3.26 0.93 
20 L2321F,V2333E,Q2335H 13 -0.19 2.62 1.44 
21 L2321F,Y2324F,Q2335H 17 4.24 2.55 0.21 
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Even though none of the 21 designed sequences were predicted “fitter” than the wild–type, they were all 
close to the wild-type fitness. The computed fitness of 20 out of 21 designs resided in 95% percentile or 
higher when compared to the whole distribution of single, double, and triple mutations, suggesting that 
the protein would remain stable and functional. The sequence with the highest difference to wild-type 
fitness prediction (Design-11; V2313M, Y2324L, V2333E) was located in the 90% percentile and still 
close to WT fitness (reduction of 1.7%) and also had the maximal predicted reduction of immunogenici-
ty (immunogenicity reduction of 45%) deleting eight out of nine epitopes of identified region. The next-
best triple mutant (L2321T, I2327L, V2333E) resulted in the deletion of eight epitopes with an immuno-
genicity reduction of 42% and a fitness reduction of 1.28%.  
Figure 3: Pareto-front of de-immunized designs with k=1,2,3 mutations. Each design is a trade-off between the 
immunogenicity and the protein fitness function and represents a newly sequence (here represented as tertiary 
structures). The red spheres within the tertiary structures mark the mutated residues.  
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Previous work that aims to increase the likelihood of a functional protein after mutation design, has used 
force-field based modeling, such as FoldX31. As to distinguish the differences between FoldX and the 
employed statistical sequence model we predicted the mutation effects of the 21 designs with EVmuta-
tion and FoldX (Table 1). EVmutation’s predictions only moderately correlate to those using FoldX (r = 
0.44, CI95 = [0.02, 0.73], t = 2.173, df = 20, p-value = 4.2e-2; Fig. 4). The two most deviating mutations 
between the two prediction methods were Design-11 (V2313M, Y2324L, V2333E) and Design-3 
(Y2324L, V2333E), both of which introduced a mutation at a membrane-binding site38. FoldX predicted 
these designs comparatively less deleterious than EVmutation. One explanation for this discrepancy is 
that it would be harder for force-field based methods to capture the membrane binding constraints unless 
they were in the structure used.  
r = 0.44, CI95 = [0.02, 0.73]
t = 2.173, df = 20
p-value = 4.2e-2
Energy (EVmutation)
Fo
ldX
Figure 4: EVmutation and FoldX prediction correlations. The red line is a fitted linear regression, and the red tube represents 
its 95-confidence interval. The orange-circled dots are the two mutational designs with the highest discrepancy. FoldX pre-
dicted these two mutations less deleterious compared EVmutation, although both designs introduced a mutation at a mem-
brane-binding site. 
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Experimental validation 
To test the designs, we synthesized overlapping 15-mer peptides containing the introduced mutations 
and their wild-type counterparts. The peptides maximally covered the predicted epitopes around the mu-
tations of all designed constructs that contained one and two mutations (Supplementary Table S2). The 
affinity of these peptides to the three HLA alleles was measured at time zero and after 24 hours (Meth-
ods, Supplementary Table S3 and S4). We linearly combined the measured affinity scores across alleles 
for each peptide respectively to produce a score that summarizes the overall immunogenicity (Fig. 5A).  
(A)
r = 0.85, CI95 = [0.35, 0.97]
t = 3.870, df = 6
p-value = 8.3e-3
r = 0.76, CI95 = [0.47, 0.90]
t = 4.848, df = 17
p-value = 1.5e-4
(B)
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Figure 5: (A) Correlation of experimental and predicted immunogenicity of each peptide. The immunogenicity score 
of a peptide is defined as the linear combination of the individual experimental scores of each HLA allele h ∈ H. (B) 
Correlation of experimental and predicted immunogenicity of the whole redesigned region. The summarized immuno-
genicity score of the whole region is the linear combination of the overlapping peptides used to reconstruct the region, 
normalized by total number of peptides used. The red lines are a fitted linear regression and the red tubes represent 
their 95-confidence interval. 
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Overall, the measured and predicted immunogenicity of the tested peptides correlated well with r = 0.76 
(CI95 = [0.47, 0.90], t = 4.848, df = 17, p-value = 1.5e-4; Fig. 5A). The highest reduction of 86.04% was 
observed for M-8 at while the highest increase in immunogenicity of 87.01% was observed for M-4 con-
firming the predicted decrease of 86.87% for M-8 and predicted increase of 86.37% for M-4.  
Next we compared the predicted and measured gain or loss in immunogenicity for the whole region by 
reconstructing the targeted region using overlapping peptides. The measured scores were linearly com-
bined (as previously) and then normalized to the number of overlapping peptides used in the reconstruc-
tion (Fig. 5B). The difference in the measured scores between the wild type and mutant regions can be 
thought of as a proxy for gain or loss in immunogenicity and correlate well to the predicted changes  (r = 
0.85 (CI95 = [0.35, 0.97], t = 3.870, df = 6, p-value = 8.3e-3; Fig. 5B). Measurements made after 24 
hours were very similar (r = 0.94, CI95 = [0.86, 0.98], t = 11.81, df = 17, p-value = 1.3e-09).  
DISCUSSION 
This work introduced a novel method to reduce a protein’s immunogenicity while maintaining its func-
tionality requiring only sequence information of the target protein. The method uses a new immunogen-
icity objective that is, in contrast to previous approaches, accounting for relative epitope strength and 
integrates HLA allele frequency information of a target population. Since the HLA distribution can dif-
fer tremendously between populations this will influence the immunogenicity of a protein and hence T-
cell epitopes that are prioritized during the de-immunization process.  
The fact the highly immunogenic region, a prior identified during an in silico screening and inde-
pendently described by others19, coincides with a highly evolutionary connected as well as functionally 
important region underlines the need for methods that are capable of incorporating functional and struc-
tural integrity prediction in the de-immunization process. The de-immunization model introduced 
demonstrates the power of such approaches; the predicted immunogenicity of the complete domain 
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could be reduced by 45% without disrupting the fitness landscape extensively. Moreover, the observed 
highly significant correlations between measured and predicted immunogenicity both on individual pep-
tide and (reconstructed) segment level affirmed that the underlying assumptions made by the model are 
sufficient to predict the influence of mutation in terms of immunogenicity.  
In the particular case of this Factor VII domain, we found no advantage to structure and force-field base 
approaches to assessing the effect of clinical mutation classification; structure-based approaches may 
even be a disadvantage when structure information is incomplete (e.g., binding partners not present). 
This suggests that sequence information may be sufficient for de-immunization design, and is consistent 
with the previous observation that sequences alignments can be used to identify constrained interacting 
residues across biomolecules as well as the effect of mutations30,39. However, high-quality diverse se-
quence alignments are not always available.  
 
In summary, we proposed a novel de-immunization model that integrates quantitative immunogenicity 
optimization with sequence-based fitness optimization and used the approach to design novel C2 do-
mains of Factor VIII that can be further validated for clinical application using mouse models or T-cell 
proliferation assays based on PBMCs of HA patients. The approach will allow bioengineers to reliably 
explore the design space of the target protein to select promising candidates for experimental evaluation. 
METHODS 
Derivation of the immunogenicity objective 
The first objective of the de-immunization model is an adaptation of the immunogenicity score intro-
duced by Toussaint et al. for epitope selection in the context of in silico vaccine design and is defined as 
follows 34:  
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𝐼 𝐸 𝐻 ,𝑃𝐻 = 𝑝ℎ ∙ 𝑖𝑒,ℎ,ℎ∈𝐻𝑒∈𝐴   
with 𝐴 being a set of epitopes, 𝑖𝑒,ℎ the immunogenicity of epitope 𝑒 ∈ 𝐴 bound to HLA allele ℎ ∈ 𝐻 . It 
assumes that each epitope independently influences the immune response with respect to all considered 
HLA alleles. The contribution of an HLA allele ℎ ∈  𝐻  is directly proportional to its probability 𝑝ℎ of 
occurring within the target population 𝐻 . 
Derivation of the protein fitness objective 
The second objective is a evolutionary statistical energy of sequences computed by a pairwise maximum 
entropy model of protein families. Under these family-specific models, the probability for a protein se-
quence (X1, ..., Xn) of length 𝑛 is defined as 
𝑃 𝑋1, …𝑋𝑛 =  1𝑍  𝑒−𝐸(𝑥) 
𝐸 𝑋 =  𝐽𝑖𝑗(𝑋𝑖,𝑋𝑗) + ℎ𝑖(𝑋𝑖)1≤𝑖≤𝑛1≤𝑖≤𝑗≤𝑛   
where the pair coupling parameters Jij(Xi, Xj) describe evolutionary co-constraints on the amino acid con-
figuration of residue pairs i and j for all amino acids and the parameters hi(Xi) corresponds to single-site 
amino acid constraints. The partition function 𝑍 is a global normalization factor summing over all pos-
sible amino acid sequences of length n23,24. The parameters Jij and hi are inferred from a protein family 
sequence alignment using an iterative approximate maximum likelihood inference scheme (pseudo-
likelihood maximization) under l2-regularization to prevent overfitting. Given an inferred probability 
model for a family, the statistical energy −𝐸(𝑋) can be used to quantify the fitness of specific sequenc-
es. Recent work has demonstrated that changes of E(X) quantitatively correspond to the experimental 
phenotypic consequences of mutations, including effects on protein stability and organismal growth30. In 
order to maintain protein function while minimizing immunogenicity, the second objective function is 
defined as the minimization of −𝐸(𝑋).   
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Evolutionary coupling (EC) strength between pairs of positions i and j is computed using the Frobenius 
norms of the matrices Jij with subsequent correction for finite sampling and phylogenetic effects (aver-
age product correction)26. The evolutionary couplings are predictive of residue proximity in many pro-
tein families, and the cumulative score of one position to all others (EC enrichment score) is indicative 
of functionally and structurally important positions 26. 
Derivation of the integer linear program representation of the de-immunization model  
We solve the stated de-immunization problem as a bi-objective mixed integer linear program 
(BOMILP). Solving a BOMILP finds all Pareto-optimal solutions to linear objectives with affine con-
straints and additional integrality constraints on a subset of the variables. The model is based on Kings-
ford et al.’s ILP formulation of the side-chain placement problem 40. But instead of selecting energetical-
ly favorable rotamers, we encode each state of the model as a possible amino acid substitution at each 
position. A binary decision variable 𝑥𝑖,𝑎 for each position 𝑖 ∈  {1. . 𝑛} and each possible variation 𝑎 ∈
 𝑀𝑖 is introduced with 𝑥𝑖,𝑎 = 1 if this variant will be part of the final mutant 𝑆′. An additional binary 
variable is introduced for each pair of variants and positions notated 𝑤𝑖,𝑗,𝑎,𝑏 with 𝑤𝑖,𝑗,𝑎,𝑏 = 1 if variant 𝑎 
at position 𝑖 and variant 𝑏 at position 𝑗 have been selected as part of the solution 𝑆′. These variables are 
associated with their inferred fitness terms ℎ𝑖,𝑎 and 𝐽𝑖,𝑗,𝑎,𝑏 to form the second objective function (Table 2 
O2).  
 
The immunogenicity objective, in contrast to the problem formulation of Toussaint et al., in which the 
immunogenicity of each candidate epitope 𝑒 ∈  𝐴 could be pre-calculated, does not have an easy ILP 
representation. It has to directly incorporate prediction methods to approximate the immunogenicity of 
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the current mutant 𝑆′. Therefore, we use TEPITOPEpan33 as internal prediction engine since it has been 
demonstrated to have good predictive power and can be easily integrated into the ILP framework. More 
advanced, machine learning-based prediction models cannot readily be integrated into the problem for-
mulation. With linear (matrix-based) methods, the integration is possible by scoring each peptide gener-
ated with a sliding window of width 𝑒𝑛 for each allele ℎ ∈  𝐻  independently by summing over 
TEPITOPEpan’s position specific scoring matrix 𝛷 ℎ, 𝑎, 𝑗 →  ℝ≥0 for amino acid 𝑎 ∈  𝑀𝑖+𝑗  at posi-
tion 𝑖 +  𝑗 with 𝑖 ∈  1. . (𝑛 − 𝑒𝑛)  and 𝑗 ∈  {0. . (𝑒𝑛  −  1)}. To only consider predicted binding 
epitopes, the binding threshold 𝜏ℎ of each HLA allele ℎ ∈  𝐻  is subtracted from the sum score of an 
epitope and the maximum of 0 and the cumulative score is taken. The sum of all epitope scores for a par-
ticular allele ℎ ∈  𝐻  is than weighted by its population probability 𝑝ℎ. To make the prediction scores 
comparable across HLA alleles, the position specific scoring matrices of TEPITOPEpan were z-score 
normalized and the binding thresholds adjusted accordingly. The final immunogenicity score consists of 
the sum of all allele-wise weighted sums (Table 2, O1). 
 
Table 2: Bi-objective integer linear program formulation of the de-immunization problem. 
Definition:   
Objectives:   
(O1) minx,w     ph ∙ max 0, xi,a ∙ ϕ h, a, ja∈Mi+jen-1j=0 -τmn-eni=1h∈H   (O2) minx,w     xi,a ∙ hi,a ni=1 + wi,j,a,b ∙ Ji,j,a,b1≤i<j≤nni=1   
   
Constraints:   (C1)  xi,a = 1a∈ Mi  ∀ i ∈ {1. . n}  (C2)  wi,j,a,b=xi,ab∈Mj  ∀ i, a ∈ Mi , 𝑖 > 𝑗 ∈ {1. . n}  (C3)  wi,j,a,b=xj,ba∈Mi  ∀ j, b ∈ Mi , 𝑗 < 𝑖 ∈ {1. . n}   (C4)  1-xi,a ≤ ka∈Wini=1    
 
 20 
 
To construct a consistent model, three constraints have to be introduced guaranteeing that only one ami-
no acid per position is selected (Table 2, C1) and that only pairwise interactions are considered for se-
lected variants (i.e., 𝐽𝑖,𝑗,𝑎,𝑏,  =  1 ↔  𝑥𝑖,𝑎  =  1 ⋀ 𝑥𝑗,𝑏  =  1, see Table 2 C2 and C3). Constraints C2 and 
C3 can be further relaxed by dividing the pairwise fitness values into positive and negative sets 40, which 
is done in practice but disregarded here for ease of presentation. To be able to restrict the mutant to a 
specific number of introduced variations, constraint C4 limits the number of deviating amino acids to the 
wild type sequence 𝑊 . A detailed formulation of the complete optimization problem can be found in 
Supplementary Table S6. 
Pre-processing 
To reduce the search space, a filtering approach based on position specific amino acid appearance fre-
quency 𝑓𝑖 𝑎 , i.e. conservation can be applied. Only amino acids at position 𝑖 ∈  {1. . 𝑛} exceeding a 
certain frequency threshold 𝜁  are considered as possible substitution at a site. Hence, the set of possible 
substitutions per position is defined as 𝑀𝑖 ∶=  𝑎 ∈  𝛴 𝑓𝑖(𝑎)  ≥  𝜁}. The wild type amino acid is addi-
tionally added if it does not exceed the frequency threshold. This filtering is based on the assumption 
that variants that are not or infrequently observed are harmful due to either destabilizing effects, reduc-
tion of function, or intervening effects with interaction partners. 
Solving a bi-objective integer program 
Special strategies have to be applied to solve a BOMILP. Popular methods to solve discrete multi-
objective problems include the 𝜀-constraint41, perpendicular search42, and the augmented weighted Che-
bychev method43. All have their own limitations. The recently published rectangle splitting approach 
tries to overcome these44,45. For solving the de-immunization problem, we developed a parallel two-
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phase version of the rectangle-splitting approach that can exploit the parallel nature of the algorithm and 
can effectively utilize modern distributed computing resources. In the following we sketch the newly 
developed two-phase approach. 
 
First we introduce necessary notations and concepts (adopted from Boland et. al.). Let 𝒛𝟏 = (𝑧11, 𝑧21) and 
𝒛2 = (𝑧12, 𝑧22) be two points in solution space with 𝑧11  ≤  𝑧12 and 𝑧22  ≤  𝑧21. Further we define 𝑅(𝒛1, 𝒛2) to 
be the rectangle spanned by 𝒛𝟏 and 𝒛𝟐. A nondominated point within 𝑅(𝒛1, 𝒛2) can be found with the 
following sequential operation (see proof in44): 
 
1  𝑧1 =  min𝑥∈𝜒 𝑧1(𝑥) 𝑠. 𝑡: 𝑧 𝑥 ∈ 𝑅(𝒛𝟏, 𝒛𝟐)  (2) 𝑧2 =  min𝑥∈𝜒  𝑧2(𝑥)𝑠. 𝑡: 𝑧 𝑥 ∈ 𝑅 𝒛𝟏, 𝒛𝟐  𝑎𝑛𝑑 𝑧1 ≤ 𝑧1
 
 
These operations will be denoted as 𝒛 =  lex min𝑥∈𝑋 𝑧1 𝑥 , 𝑧2 𝑥 : 𝑧 𝑥 ∈ 𝑅(𝒛𝟏, 𝒛𝟐) .  
As a first step of the two-phase parallel rectangle-splitting approach the boundaries of the Pareto front 
are calculated by solving 
𝒛𝑇 =  lex min𝑥∈𝑋 𝑧1 𝑥 , 𝑧2 𝑥 : 𝑧 𝑥 ∈ 𝑅((−∞,∞), (−∞,∞))  
and  
𝒛𝐵 =  lex min𝑥∈𝑋 𝑧2 𝑥 , 𝑧1 𝑥 : 𝑧 𝑥 ∈ 𝑅((−∞,∞), (−∞,∞))  
in parallel (Fig. 6A). Then, the search space within 𝑅(𝒛𝑇 , 𝒛𝐵) is evenly constraint based on boundary 
conditions enforced w.l.o.g. on 𝑧1 (Fig. 6B). The boundaries are calculated for a predefined number of 
constraints 𝑚 with: 
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𝜏𝑖𝑧1 = 𝑧1𝑇 + 𝑖 ∙ (𝑧1𝐵 − 𝑧1𝑇 )𝑚   𝑤𝑖𝑡ℎ 1 ≤ 𝑖 ≤ 𝑚. 
 
Each section of the separated search space can be independently searched by solving zi= lex 
minx∈X z1 x ,z2 x : z x ∈R (τiz1,z2T ,zB)  and the resulting new nondominated points can be used as initial 
approximation of the Pareto front. The found nondominated points might contain duplicates and also 
might not resemble the complete Pareto front. Therefore, it is necessary to perform a refinement of the 
Pareto front to find the remaining nondominated points. To this end, the nondominated points are sorted 
in nondecreasing order such that 𝑧11 ≤ 𝑧12 ≤ ⋯ ≤ 𝑧1𝑘. Each consecutive pair of points spans a search rec-
tangle 𝑅(𝒛𝒊, 𝒛𝒋) with 𝑖 ≤ 𝑗. These rectangles can now be searched in parallel by the rectangle-splitting 
algorithm (Fig. 6C). The search rectangles are split in half. First, the bottom half 𝑅𝐵  is searched by solv-
(A) (B) (D)(C)
Figure 6: Depiction of the parallel two-phase rectangle splitting approach. (A) First, the boundaries of the Pareto front 
are identified. (B) Then, the space between the boundaries is evenly divided and searched in parallel for nondominated 
points using the ε-constraint method. (C) The identified nondominated points are used to initiate rectangle search spac-
es which can be processed in parallel using the standard rectangle-splitting approach, by splitting the rectangle in half 
and searching independently the bottom and top half (D). If the corner points of the rectangles are found during the 
search, it is proofs, that no further nodominated point resides within the search space and all points have been identi-
fied.  
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ing: 
𝒛1 =  lex min𝑥∈𝑋 𝑧1 𝑥 , 𝑧2 𝑥 : 𝑧 𝑥 ∈ 𝑅 𝑧1𝑖 , 𝑧2
𝑖 + 𝑧2𝑗2 , 𝒛𝑗  
If a nondominated point is found, the upper half 𝑅𝑇  is further restricted and spans now 
R zi, z1i -ϵ, z2i +z2j2  in which 𝒛2 =  lex minx∈X 𝑧2 𝑥 , 𝑧1 𝑥 : 𝑧 𝑥 ∈ 𝑅 𝒛𝑖, 𝑧1𝑖 − 𝜖, 𝑧2𝑖 +𝑧2𝑗2  is 
searched. Each newly found point spans a new independent search rectangle 𝑅(𝒛𝑖, 𝒛2) and 𝑅(𝒛1, 𝒛𝑗) with 
its adjacent point. These rectangles are searched in parallel with the described procedure (Fig. 6D). If the 
search operation yielded the known point 𝒛𝑗  for 𝑅 𝑧1𝑖 , 𝑧2𝑖 +𝑧2𝑗2 , 𝒛𝑗  and 𝒛𝑖 for R zi, z1i -ϵ, z2i +z2j2  
accordingly proofs that the area does not contain further nondominated points. The search procedure is 
carried out until the complete search space has been explored.  
Inference of the maximum entropy sequence model  
Multiple sequence alignments (MSA), created by JackHMMER46, were used for the inference of the 
maximum entropy models of the Factor VIII C2-domain (residues 2,188-2,345 of FA8_HUMAN, Sup-
plementary material S1). To optimize residue coverage and MSA diversity, the alignment was created 
using five search iterations at an E-value threshold of 10-20. Sequences with 70% or more gaps and col-
umns with over 50% gaps were excluded from subsequent statistical inference. To reduce the influence 
of sampling bias in the inference step, sequences were clustered at a 90% identity threshold (theta 0.9), 
and reweighted by the inverse of the number of cluster members. The parameters of the pairwise maxi-
mum entropy model and evolutionary couplings were then inferred using EVfoldPLM 47 with pseudo-
likelihood maximization48 (Supplementary material S1). Substitution effects were derived by calculating 
the difference between the wild-type and the mutant statistical energy30. The validity of the maximum 
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entropy model was verified by using the precision of the inferred top evolutionary couplings (ECs) be-
tween residue pairs compared to an existing 3D structure. To identify the top ECs a Gaussian-lognormal 
mixture model was inferred based on the overall score distribution27 and the ECs within the tail of the 
distribution (ECs with a probability ≥ 0.90 of belonging to the lognormal) were used for model quality 
assessment27. 
Hemophilia a severity data and regression analysis 
Single point mutation data with known patient severity status was extracted from the Factor VIII variant 
database (http://www.factorviii-db.org). The data was filtered for mutations residing within the C2 do-
main, which resulted in 40 data points in total (Supplementary Table S5). The severity status of each pa-
tient was determined based on a one-stage Factor VIII:C and categorized into three classes – severe 
(<1%), moderate (1-5%), and mild (>5%). The data points were unevenly distributed across the classes 
with 15 severe, 8 moderate, and 17 mild cases.  
 
To train and validate the multinomial and logistic regression models, the data was randomly divided into 
training and test set (70:30%-split) in a stratified manner. This process was repeated two hundred times 
and the prediction performance averaged over the runs. 
Experimental design 
In order to experimentally verify our in silico predictions for Factor VIII, we utilized the commercial 
REVEAL HLA-Peptide binding assay of ProImmune (www.proimmune.com). In addition to binding, 
stabilities of HLA-peptide complexes were also investigated. Peptides were synthesized using the PEP 
screen custom library synthesis method, yielding high purity peptides for experimental analysis. HLA-
peptide binding was assessed for the three HLA-DRB1 alleles used in this study (DRB1*1501, 
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DRB1*0301 and DRB1*0701). In short, the method compares the affinity of the studied peptide to the 
affinity of a high-affinity control peptide. Each peptide is then scored for binding to a certain HLA mol-
ecule relative to the score of the control peptide, and reported as the percentage of the signal generated 
by the control peptide. In order to assess the stability of binding, the amount of bound peptide is meas-
ured at time zero and after 24 hours. From these measurements a stability index is calculated. 
Implementation 
The two-phase rectangle-splitting solver was implemented in Python 2.7 using the CPLEX package, 
Numpy 1.4, and Polygon 2.0.6 package. CPLEX 12.6 was used as backend to solve the BOMILP mod-
els.  
 
Structure-based fitness prediction for validation purposes of the de-immunized Factor VIII C2 domain 
constructs were performed with FoldX31 using default settings for the obtained mutations. TEPITOPE-
pan 1.0 was used for epitope prediction.  
Statistical analysis 
The multinomial and logistic models were fit and evaluated using Scikit-learn 0.1849. The statistical 
analysis was conducted with R 3.0.2. Statistical significance was considered at 𝛼 = 0.05. The specific 
statistical tests used are indicated in the figures or in the results section. 
Code availability 
The solver implementation, the ILP model in AMPL format, and the instances solved are available at 
https://github.com/FRED-2/EVdeimmunization released under a 3-claus BSD license. 
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ADDITIONAL INFORMATION 
Material S1: The long-range evolutionary couplings of Factor VII C2 domain, and the multiple se-
quence alignments used for model inference. 
Table S2: Known Factor VIII C2 domain single point mutation with severity status, and predicted statis-
tical energy change with EVmutation and FoldX. 
Table S3: Synthesized peptides sequences. 
Table S4: Experimental immunogenicity score measured per peptide and HLA allele. 
Table S5: Summarized experimental immunogenicity scores of the reconstructed immunogenic region. 
Material S6: Detailed description of the de-immunization BOMILP formulation  
ABBRIVIATIONS 
ADA   Anti-drug antibody 
BOMILP  Bi-objective mixed integer linear program 
CD   Cluster of differentiation 
EC   Evolutionary Couplings 
HA   Hemophilia A 
HLA   Human leucocyte antigen 
ILP   Integer linear programming 
mAb   Monoclonal antibody 
MSA   Multiple sequence alignment 
PBMC   Peripheral blood mononuclear cell 
 
